Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
JAB-8263 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
JAB-8263: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NC-318 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
NC-318: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NSC-706744 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
NSC-706744: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IGV-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
IGV-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AZD-9567 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AZD-9567: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Recombinant humanized anti-VEGF monoclonal antibody(Stainwei Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Recombinant humanized anti-VEGF monoclonal antibody(Stainwei Biotech): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
LM11A-31 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
LM11A-31: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PDA-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
PDA-002: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anti-CD3/anti-EGFR -activated T cells(Barbara Ann Karmanos Cancer Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Anti-CD3/anti-EGFR -activated T cells(Barbara Ann Karmanos Cancer Institute): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
MHB036C Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
MHB036C: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
KW-045 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
KW-045: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IRX-4204 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
IRX-4204: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.